The Cancer Research Machine Trump Is Gutting Just Delivered a Big Breakthrough
A recent breakthrough in pancreatic cancer treatment was announced at a Chicago convention, where a new drug called daraxonrasib was shown to nearly double survival time for patients. Despite this promising development, concerns arise as the Trump administration's funding cuts threaten future cancer research. The findings highlight both the potential for progress in treating previously deemed 'undruggable' cancers and the risks posed by reduced federal support for scientific research.
- ▪Daraxonrasib has nearly doubled survival time for pancreatic cancer patients who have undergone chemotherapy.
- ▪Patients treated with daraxonrasib survived an average of 13.2 months compared to 6.7 months with standard secondary chemotherapy.
- ▪The Trump administration has been criticized for undermining federal funding for scientific research, which could impact future cancer breakthroughs.
Opening excerpt (first ~120 words) tap to expand
The BreakdownThe Cancer Research Machine Trump Is Gutting Just Delivered a Big BreakthroughThere’s new hope for one of the deadliest cancers. But Trump’s war on research puts future discoveries at risk.Jonathan CohnJun 03, 2026332527Share(Photo illustration by The Bulwark / Photos: Getty)IT IS NOT EASY TO OVERWHELM CANCER SCIENTISTS, a world-weary bunch who are constantly dealing with setbacks in their experiments—and, all too frequently, deaths among their patients. But it happened on Sunday morning, inside a darkened Chicago convention hall, when Harvard-based researcher Brian Wolpin announced the results of clinical trials for a drug called daraxonrasib.Wolpin spoke in a monotone, addressing fellow oncologists from around the world.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at The Bulwark.
Discussion
0 commentsMore from The Bulwark
